Top

The European Journal of Health Economics

Published in:

01-05-2014 | Original Paper

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics

Authors: Mandel D. Michael, Anita Bálint, Barbara D. Lovász, László Gulácsi, Bálint Strbák, Petra A. Golovics, Klaudia Farkas, Zsuzsanna Kürti, Blanka K. Szilágyi, Anna Mohás, Tamás Molnár, Péter L. Lakatos

Published in: The European Journal of Health Economics | Special Issue 1/2014

Abstract

Background and aims

To assess work disability (WD) rates in an inflammatory bowel disease (IBD) cohort involving patients with Crohn’s disease (CD) or ulcerative colitis (UC) cohort and to identify possible clinical or demographic factors associated with WD. To our knowledge, this is the first study from Eastern Europe that has estimated indirect costs in IBD.

Methods

Data from 443 (M/F: 202/241, CD/UC: 260/183, mean age: 35.5 (CD) and 40.5 (UC) years, biological drug exposure 31.2/11.5 %) consecutive patients were included. WD data were collected by questionnaire and the work productivity and activity impairment instrument. Disability pension (DP) rates in the general population were retrieved from public databases.

Results

The overall DP rate in this IBD population was 32.3 %, with partial disability in 24.2 %. Of all DP events, 88.8 % were directly related to IBD. Overall, full DP was more prevalent in IBD (RR: 1.51, p < 0.001) and CD (RR: 1.74, p < 0.001) but not in UC compared to the general population and also in CD compared to UC (OR 1.57, p = 0.03). RR for full DP was increased only in young CD patients (RR_{<35 year olds}: 9.4; RR_{36–40 year olds}: 9.4 and 5.6, p < 0.01 for both). In CD, age group, previous surgery, disease duration, frequent relapses, and the presence of arthritis/arthralgia were associated with an increased risk for DP. Among employed patients, absenteeism and presenteeism was reported in of 25.9 and 60.3 % patients, respectively, leading to a 28 % loss of work productivity and a 32 % activity loss, and was associated with disease activity and age group. Average cost of productivity loss due to disability and sick leave with a human capital approach was 1,450 and 430 €/patient/year in IBD, respectively (total productivity loss 1,880 €/patient/year), the costs of presenteeism were 2,605 (SD = 2,770) and 2,410 (SD = 2,970) €/patient/year in CD and UC, respectively.

Conclusion

Risk of DP was highly increased in young CD patients (sixfold to ninefold). Previous surgery and presence of arthritis/arthralgia was identified as risk factors for DP. Work productivity is significantly impaired in IBD and is associated with high productivity loss.

Miheller, P., Kiss, L.S., Juhasz, M., Mandel, M., Lakatos, P.L.: Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev. Clin. Immunol. 9(1), 65–75 (2013)PubMedCrossRef

Kiss, L.S., Lakatos, P.L.: Natural history of ulcerative colitis: current knowledge. Curr. Drug Targets 12(10), 1390–1395 (2011)PubMedCrossRef

Burisch, J., Jess, T., Martinato, M., Lakatos, P.L., ECCO -EpiCom: The burden of inflammatory bowel disease in Europe. J. Crohns Colitis 7(4), 322–337 (2013)PubMedCrossRef

Bouguen, G., Levesque, B.G., Feagan, B.G., Kavanaugh, A., Peyrin-Biroulet, L., Colombel, J.F., Hanauer, S.B., Sandborn, W.J.: Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin. Gastroenterol. Hepatol. (2013). doi:10.1016/j.cgh.2013.09.006

Bernstein, C.N., Loftus Jr, E.V., Ng, S.C., Lakatos, P.L., Moum, B.: Hospitalisations and surgery in Crohn’s disease. Gut 61(4), 622–629 (2012)PubMedCrossRef

Boonen, A., Dagnelie, P.C., Feleus, A., Hesselink, M.A., Muris, J.W., Stockbrügger, R.W., Russel, M.G.: The impact of inflammatory bowel disease on labor force participation: results of a population sampled case–control study. Inflamm. Bowel Dis. 8, 382–389 (2002)PubMedCrossRef

Ananthakrishnan, A.N., Weber, L.R., Knox, J.F., Skaros, S., Emmons, J., Lundeen, S., Issa, M., Otterson, M.F., Binion, D.G.: Permanent work disability in Crohn’s disease. Am. J. Gastroenterol. 103(1), 154–161 (2008)PubMedCrossRef

Bernklev, T., Jahnsen, J., Henriksen, M., Lygren, I., Aadland, E., Sauar, J., Schulz, T., Stray, N., Vatn, M., Moum, B.: Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 12(5), 402–412 (2006)PubMedCrossRef

Høivik, M.L., Moum, B., Solberg, I.C., Henriksen, M., Cvancarova, M., Bernklev, T., IBSEN Group: Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 62(3), 368–375 (2013)PubMedCrossRef

10.

van der Valk, M.E., Mangen, M.J., Leenders, M., Dijkstra, G., van Bodegraven, A.A., Fidder, H.H., de Jong, D.J., Pierik, M., van der Woude, C.J., Romberg-Camps, M.J., Clemens, C.H., Jansen, J.M., Mahmmod, N., van de Meeberg, P.C., van der Meulen-de Jong, A.E., Ponsioen, C.Y., Bolwerk, C.J., Vermeijden, J.R., Siersema, P.D., van Oijen, M.G., Oldenburg, B., on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis: Risk factors of work disability in patients with inflammatory bowel disease—a Dutch nationwide web-based survey: work disability in inflammatory bowel disease. J. Crohns Colitis (2013). doi:10.1016/j.crohns.2013.11.019 PubMed

11.

Siebert, U., Wurm, J., Gothe, R.M., Arvandi, M., Vavricka, S.R., von Känel, R., Begré, S., Sulz, M.C., Meyenberger, C., Sagmeister, M., Swiss, I.B.D., Cohort Study Group: Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study. Inflamm. Bowel Dis. 19(4), 847–855 (2013)PubMedCrossRef

12.

Stjernman, H., Tysk, C., Almer, S., et al.: Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn’s disease. Eur. J. Gastroenterol. Hepatol. 23, 671–679 (2011)PubMedCrossRef

13.

Gibson, P.R., Vaizey, C., Black, C.M., Nicholls, R., Weston, A.R., Bampton, P., Sparrow, M., Lawrance, I.C., Selby, W.S., Andrews, J.M., Walsh, A.J., Hetzel, D.J., Macrae, F.A., Moore, G.T., Weltman, M.D., Leong, R.W., Fan, T.: Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J. Crohns Colitis (2013). doi:10.1016/j.crohns.2013.11.017

14.

Israeli, E., Graff, L.A., Clara, I., Walker, J.R., Lix, L.M., Targownik, L.E., Bernstein, C.N.: Low prevalence of disability among patients with inflammatory bowel diseases a decade after diagnosis. Clin. Gastroenterol. Hepatol. (2013). doi:10.1016/j.cgh.2013.12.009

15.

Lennard-Jones, J.E.: Classification of inflammatory bowel disease. Scand. J. Gastroenterol. 24(suppl 170), 2–6 (1989)CrossRef

16.

Silverberg, M.S., Satsangi, J., Ahmad, T., Arnott, I.D., Bernstein, C.N., Brant, S.R., Caprilli, R., Colombel, J.F., Gasche, C., Geboes, K., Jewell, D.P., Karban, A., Loftus Jr, E.V., Peña, A.S., Riddell, R.H., Sachar, D.B., Schreiber, S., Steinhart, A.H., Targan, S.R., Vermeire, S., Warren, B.F.: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can. J. Gastroenterol. 19(Suppl A), 5–36 (2005)

17.

Stange, E.F., Travis, S.P.L., Vermeire, S., Beglinger, C., Kupcinkas, L., Geboes, K., Barakauskiene, A., Villanacci, V., Von Herbay, A., Warren, B.F., Gasche, C., Tilg, H., Schreiber, S.W., Schölmerich, J., Reinisch, W., European Crohn’s and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 55(suppl 1), 11–15 (2006)

18.

Best, W.R., Becktel, J.M., Singleton, J.W., Kern Jr, F.: Development of a Crohn’s disease activity index: national cooperative Crohn’s disease study. Gastroenterology 70, 439–444 (1976)PubMed

19.

Vermiere, S., Schreiber, S., Sandborn, W.J., Dubois, C., Rutgeerts, P.: Correlation between the Crohn’s disease activity and harvey-bradshaw indices in assessing Crohn’s disease severity. Clin. Gastroenterol. Hepatol. 8, 357–363 (2010)CrossRef

20.

Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M.: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625–1629 (1987)PubMedCrossRef

21.

Reilly, M.C., Zbrozek, A.S., Dukes, E.M.: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5), 353–365 (1993)PubMedCrossRef

22.

Reilly Associates’s WPAI translations webpage (2014). http://www.reillyassociates.net/WPAI_Translations.html. Accessed 18.01.2014

23.

Hungarian Central Administration of National Pension Insurance webpage (2014). http://ww.onyf.hu/index.php?module=news&action=getfile&fid=9762&rand=51d06e367983259f36f1f0e73a25cb4b. Accessed 18.01.2014

24.

Hungarian Central Administration of National Pension Insurance webpage (2014). https://www.onyf.hu/index.php?module=news&action=getfile&fid=9763&rand=24d24e51f4056da48ae0e96edd6743b0. Accessed 18.01.2014

25.

Koopmanschap, M.A., Rutten, F.F.: A practical guide for calculating indirect costs of disease. Pharmacoeconomics 10(5), 460–466 (1996)PubMedCrossRef

26.

Koopmanschap, M.A., Rutten, F.F., van Ineveld, B.M., van Roijen, L.: The friction cost method for measuring indirect costs of disease. J. Health Econ. 14(2), 171–189 (1995)PubMedCrossRef

27.

Lofland, J.H., Pizzi, L., Frick, K.D.: A review of health-related workplace productivity loss instruments. Pharmacoeconomics 22(3), 165–184 (2004)PubMedCrossRef

28.

Brodszky, V., Bálint, P., Géher, P., Hodinka, L., Horváth, G., Koó, É., Péntek, M., Polgár, A., Seszták, M., Szántó, S., Ujfalussy, I., Gulácsi, L.: Disease burden of psoriatic arthritis compared to rheumatoid arthritis. Hung. Exp. Rheumatol. Int. 30(2), 199–205 (2009)CrossRef

29.

Péntek, M., Kobelt, G., Czirják, L., Szekanecz, Z., Poór, G., Rojkovich, B., Polgár, A., Genti, G., Kiss, C.G., Brodszky, V., Májer, I., Gulácsi, L.: Costs of rheumatoid arthritis in Hungary. J. Rheumatol. 34(6), 1437 (2007)PubMed

30.

Filipovic, I., Walker, D., Forster, F., Curry, A.S.: Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology 50(6), 1083–1090 (2011)PubMedCrossRef

31.

Puolakka, K., Kautiainen, H., Pekurinen, M., Möttönen, T., Hannonen, P., Korpela, M., Hakala, M., Arkela-Kautiainen, M., Luukkainen, R., Leirisalo-Repo, M., FIN-RACo Trial Group: Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients’ sickness absence and gross income: experience from the FIN-RACo trial. Ann. Rheum. Dis. 65(7), 899–904 (2006)PubMedCentralPubMedCrossRef

32.

Verstappen, S.M., Boonen, A., Verkleij, H., Bijlsma, J.W., Buskens, E., Jacobs, J.W., Utrecht Rheumatoid Arthritis Cohort Study Group: Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann. Rheum. Dis. 64(12), 1754–1760 (2005)PubMedCentralPubMedCrossRef

33.

Gulácsi, L., Orlewska, E., Péntek, M.: Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. Eur. J. Health Econ. 13(5), 525–531 (2012)PubMedCrossRef

34.

Krol, M., Brouwer, W., Rutten, F.: Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics 31(7), 537–549 (2013)PubMedCrossRef

Title: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
Authors: Mandel D. Michael
Anita Bálint
Barbara D. Lovász
László Gulácsi
Bálint Strbák
Petra A. Golovics
Klaudia Farkas
Zsuzsanna Kürti
Blanka K. Szilágyi
Anna Mohás
Tamás Molnár
Péter L. Lakatos
Publication date: 01-05-2014
Publisher: Springer Berlin Heidelberg
Published in: The European Journal of Health Economics / Issue Special Issue 1/2014
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-014-0603-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics

Abstract

Background and aims

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Special Issue 1/2014

Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary

Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres